Generic Retisert Availability

Retisert is a brand name of fluocinolone ophthalmic, approved by the FDA in the following formulation(s):

RETISERT (fluocinolone acetonide - implant;intravitreal)

Has a generic version of Retisert been approved?

No. There is currently no therapeutically equivalent version of Retisert available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Retisert. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Method for treating and/or preventing retinal diseases with sustained release corticosteroids
    Patent 6,217,895
    Issued: April 17, 2001
    Inventor(s): Guo; Hong & Ashton; Paul
    Assignee(s): Control Delivery Systems
    The present invention relates to a method for administering a corticosteroid to a posterior segment of an eye. In the method, a sustained release device is implanted to deliver the corticosteroid to the eye. The aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during release of the corticosteroid from the device.
    Patent expiration dates:
    • March 22, 2019
      ✓ 
      Patent use: TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
      ✓ 
      Drug product
  • Method for treating and/or preventing retinal diseases with sustained release corticosteroids
    Patent 6,548,078
    Issued: April 15, 2003
    Inventor(s): Hong; Guo & Paul; Ashton
    Assignee(s): Control Delivery Systems
    The present invention relates to a method for administering a corticosteroid to a posterior segment of an eye. In the method, a sustained release device is implanted to deliver the corticosteroid to the eye. The aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during release of the corticosteroid from the device.
    Patent expiration dates:
    • March 22, 2019
      ✓ 
      Patent use: TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web4)